9,134
Total Claims
$2.3M
Drug Cost
1,423
Beneficiaries
$1,623
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+6%
Cost per patient vs peers
$1,623 vs $1,524 avg
+40%
Brand preference vs peers
19.1% vs 13.7% avg
Brand vs Generic
81% generic
Brand: 1,746 claims · $2.1M
Generic: 7,388 claims · $187K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 926 | $1.2M |
| Rivaroxaban | 292 | $401K |
| Sacubitril/Valsartan | 150 | $227K |
| Evolocumab | 80 | $70K |
| Empagliflozin | 51 | $62K |
| Alirocumab | 74 | $57K |
| Metoprolol Succinate | 973 | $24K |
| Ticagrelor | 27 | $19K |
| Atorvastatin Calcium | 799 | $11K |
| Ezetimibe | 199 | $9,112 |
| Ranolazine | 58 | $8,920 |
| Valsartan | 157 | $8,734 |
| Dabigatran Etexilate Mesylate | 12 | $8,279 |
| Rosuvastatin Calcium | 338 | $7,148 |
| Diltiazem Hcl | 126 | $6,487 |
Prescribing Profile
56
Unique Drugs
$1.9M
Patient Profile
78
Avg Age
38%
Female
1.59
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data